13th week of 2013 patent applcation highlights part 51 |
Patent application number | Title | Published |
20130079243 | Fibronectin Type III Repeat Based Protein Scaffolds with Alternative Binding Surfaces - Protein scaffolds and scaffold libraries based on a fibronectin type III (FN3) repeat with an alternative binding surface design, isolated nucleic acids encoding the protein scaffolds, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders. | 2013-03-28 |
20130079244 | METHODS OF PREDICTING PREDISPOSITION TO OR RISK OF KIDNEY DISEASE - Methods are disclosed herein for detecting a genetic predisposition to focal segmental glomerulosclerosis (FSGS) or hypertensive end-stage kidney disease (ESKD) or both in a human subject, e.g., by detecting the presence of at least one single nucleotide polymorphism (SNP) in an APOL1 gene, such as the C-terminal exon of an APOL1 gene. In a further embodiment, methods are disclosed for detecting resistance of a subject to a disease associated with | 2013-03-28 |
20130079245 | Biomarkers for Ulcerative Colitis and Crohn's Disease - The present invention provides compositions and their use in diagnosing ulcerative colitis, Crohn's Disease, and inflammatory bowel disease. | 2013-03-28 |
20130079246 | Methods and Tools for Screening Agents Exhibiting an Activity on Receptors of the Tumor Necrosis Factor Receptor Superfamily - The present invention provides novel chimeric receptors and methods of screening using the chimeric receptors. The chimeric receptors comprise an extracellular domain of a tumor necrosis factor receptor superfamily (TNFRSF) receptor and an intracellular domain with kinase activity stemming from a receptor tyrosine kinase. According to an embodiment, the chimeric receptor comprises a full-length TNFRSF receptor. The present invention provides means for screening and testing of modulators of TNFRSF receptors. | 2013-03-28 |
20130079247 | METHOD AND APPARATUS FOR DELIVERY OF SUBMICROLITER VOLUMES ONTO A SUBSTRATE - A slotted pin tool, a delivery system containing the pin tool, a substrate for use in the system and methods using the pin tool and system are provided. The slotted pin tool contains a plurality of pins having slotted ends designed to fit around each loci of material deposited on a surface, such as a microarray, without contacting any of the deposited material. Sample is delivered by contacting the pin tool with the surface; the amount delivered is proportional to the velocity of the pin tool as it contacts the surface or the velocity of the liquid when movement of the pin is halted. | 2013-03-28 |
20130079248 | FLUID CONTROLLING APPARATUS AND FILTER AND BIOCHIP INCLUDING THE FLUID CONTROLLING APPARATUS - A fluid controlling apparatus including an inlet through which a fluid is introduced, a channel portion connected to the inlet, an outlet that is connected to the channel portion and through which the fluid is discharged, and at least one fluid resisting portion disposed between the inlet and the outlet, as well as a filter and a biochip including the fluid controlling apparatus. | 2013-03-28 |
20130079249 | GLYCOSYLATION ASSAY, GLYCOANALYSIS ARRAY AND AN ASSAY SYSTEM - An improved glycosylation assay, glycoanalysis array and an assay system for performing glycosylation assays glycoanalysis array. | 2013-03-28 |
20130079250 | Compound Arrays for Sample Profiling - The invention provides arrays of compound for use in profiling samples. The arrays include compounds bind to components of the samples at relatively low affinities. The avidity of compounds binding to components of the samples can be increased by forming arrays such that multivalent components of the samples (e.g., antibodies or cells) can bind to more than one molecule of a compound at the same time. When a sample is applied to an array under such conditions, the compounds of the array bind to component(s) of the sample with significantly different avidities generating a profile characteristic of the sample. | 2013-03-28 |
20130079251 | Systems and Methods for Processing Fluids - Systems and methods for processing fluid samples are disclosed. Fluid sample processing is accomplished using a series of microfluidic bump arrays include an automated and integrated system for sorting particles from a biological sample, lysing those particles to expose total RNA or DNA, purifying the RNA or DNA, processing the RNA or DNA by chemical or enzymatic modification, to select RNA or DNA molecules by size, or to generate, optionally, a sequencing library. The sequencing library is suitable for use in next generation sequencing (“NGS”). | 2013-03-28 |
20130079252 | METHODS AND SYSTEMS FOR CONTROLLING LIQUIDS IN MULTIPLEX ASSAYS - A fluidic device for conveying liquid to a well of a microplate. The device includes a support structure configured to be mounted along the microplate. The device also includes a microfluidic tube coupled to the support structure. The tube has an inlet, an outlet, and an open-sided channel that extends longitudinally therebetween. The tube has a cross-section that includes an interior contour with a gap therein. The gap extends at least partially along a length of the tube. The tube is configured to convey liquid to the well of the microplate when the tube is held in a dispensing orientation. | 2013-03-28 |
20130079253 | MICROARRAY-BASED SAMPLE ANALYSIS SYSTEM - A microarray-based sample analysis (MBSA) system includes a cartridge holder adapted to receive a replaceable cartridge that is configured to receive a detachable, replaceable sample analysis unit containing one or more reaction chambers for sample analysis; a fluid control subsystem that controls fluid flow; and an optical subsystem configured to capture an image of the microarray. | 2013-03-28 |
20130079254 | Microfluidic dialysis device - A microfluidic dialysis device that has a first channel for receiving a biological sample, a second channel, and a series of adjacent channels extending between the first channel and the second channel. Each of the adjacent channels pin a meniscus of the sample that arrests capillary flow between the first channel and the second channel. A bypass channel between the first channel and the second channel, the bypass channel joining the second channel upstream of the adjacent channels and is configured for uninterrupted capillary driven flow from the first channel to the second channel. Flow from the bypass channel reaches the meniscus pinned at each of the adjacent channels after the meniscus has formed to sequentially remove each of the menisci and allow flow from the first channel to the second channel via the adjacent channels as well as the bypass channel. | 2013-03-28 |
20130079255 | PROCESS FOR THE REMOVAL OF DEPOSITS FROM AN OIL OR GAS WELL, AND/OR FROM THE SURFACE STRUCTURES, AND/OR FROM THE EQUIPMENT CONNECTED THEREWITH, AND/OR FROM HYDROCARBON BEARING FORMATIONS - Process for the removal of deposits from an oil or gas well, and/or from surface structures, and/or from the equipment connected therewith, and/or from hydrocarbon-bearing formations, comprising: —injecting at least one oil-in-water nanoemulsion into said oil or gas well, and/or surface structures, and/or equipment connected therewith, and/or hydrocarbon bearing formations; leaving said nanoemulsion in said oil or gas well, and/or surface structures, and/or equipment connected therewith, and/or hydrocarbon bearing formations, for a predetermined time. | 2013-03-28 |
20130079256 | Filtration Control Agent And A Drilling Fluid Containing The Same - The present invention provides a filtration control agent and a drilling fluid containing the same. The filtration control agent comprises the product obtained from the reaction of water, lignite, aldehyde and sulfonate polymer at 180-220° C. and the units containing sulfonate groups in the molecular chains of sulfonate polymer are at least 30 wt %. The filtration control agent provided by the present invention features a good filtration loss reduction effect and a low viscosity effect and can improve the rheological behavior of the drilling fluid, thereby meeting the requirements of the drilling of deep wells, ultra-deep wells and ultra high pressure formations. | 2013-03-28 |
20130079257 | DISPERSANT AND A DRILLING FLUID CONTAINING THE SAME - The present invention provides a dispersant and a drilling fluid containing the dispersant. The dispersant comprises the product obtained from the reaction of water, lignin, phenol, sulfonating agent, telogen and catalyst at 140-220° C., preferably at 160-180° C.; the catalyst is one or more selected from the group consisting of sulfamic acid, p-toluenesulfonic acid and benzenesulfonic acid. The dispersant provided by the present invention not only can significantly lower the viscosity of the drilling fluid but also plays a role in reducing filtration loss. | 2013-03-28 |
20130079258 | Spray Dried Emulsifier Compositions, Methods for Their Preparation, and Their Use in Oil-Based Drilling Fluid Compositions - Spray dried emulsifier compositions are described, which have desirable emulsifying and wetting characteristics. Among other advantages, the solid particulate emulsifier compositions greatly reduce transportation costs and simplify the logistics and environmental concerns associated with shipping large volumes of solvent-containing liquids. The emulsifier comprises (1) a carboxylic acid terminated fatty amine condensate or (2) a modified tall oil or (3) a blend of (1) and (2) that is converted to its alkali or alkaline earth metal salt and spray dried. | 2013-03-28 |
20130079259 | OIL RELEASE WITH POLYETHYLENE OXIDE SEGMENT-CONTAINING N-LAUROYL AMINO ACID-BASED COMPOUNDS - Chemical compounds that are N-lauroyl amino acids containing a polyethylene oxide segment were found to have oil-releasing activity. Solutions containing these compounds may be introduced into oil reservoirs or onto oil-contaminated surface sites to release oil from oil-coated surfaces. The released oil may be recovered for further processing or waste disposal. | 2013-03-28 |
20130079260 | METHOD FOR SINGLE-STAGE TREATMENT OF SILICEOUS SUBTERRANEAN FORMATIONS - In a method of treating a sandstone-containing formation penetrated by a wellbore, a treatment fluid comprising an aqueous fluid containing a Bronsted acid, a hydrogen fluoride source and an organic acid or salt thereof that is substantially soluble in the aqueous fluid is formed. The treatment fluid contains less than about 2% of fluoride (F | 2013-03-28 |
20130079261 | SULFONATED INTERNAL OLEFIN SURFACTANT FOR ENHANCED OIL RECOVERY - A process for recovering oil from an oil-bearing formation comprises introducing into said formation an aqueous composition comprising at least one sulfonated derivative of one or more internal olefins, said internal olefins being characterized by having low amounts of tri-substitution on the olefin bond, said sulfonated derivative being obtained by sulfonating a composition comprising internal olefins of the formula: R | 2013-03-28 |
20130079262 | NOVEL MATERIALS AS ADDITIVES FOR ADVANCED LUBRICATION - This invention relates to carbon-based materials as anti-friction and anti-wear additives for advanced lubrication purposes. The materials have various shapes, sizes, and structures and are synthesized by autogenic reactions under extreme conditions of high temperature and pressure. The lubricant compositions comprise carbon-based particles suspended in a liquid hydrocarbon carrier. Optionally, the compositions further comprise a surfactant (e.g., to aid in dispersion of the carbon particles). Specifically, the novel lubricants have the ability to significantly lower friction and wear, which translates into improved fuel economies and longer durability of mechanical devices and engines. | 2013-03-28 |
20130079263 | Silicone Hydraulic Fluids - The present invention relates to a hydraulic fluid composition comprising (A) at least one polydiorganosiloxane; (B) a chlorendate diester; and (C) a lubricant compound which is an antimony or lead compound of a dialkyldithiocarbamate or dialkylphosphorodithioate. | 2013-03-28 |
20130079264 | Polymeric Phosphorus Esters for Lubricant Applications - A lubricant composition of an oil of lubricating viscosity and a polymeric phosphorus ester comprising the condensation product of a monomeric phosphorus acid or an ester thereof with a diol having two hydroxy groups separated by a chain of 4 to about 100 atoms exhibits good volatility, corrosion, wear, and/or seal performance in lubrication of a transmission. | 2013-03-28 |
20130079265 | POLYALKYL(METH)ACRYLATE FOR IMPROVING LUBRICATING OIL PROPERTIES - The invention relates to a polyalkyl (meth) acrylate for improving lubricating oil properties, which comprises repetition units which are derived from (meth) acrylates having 6 to 22 carbon atoms in the alcohol residues, and repetition units which are derived from amine derivatives of an ethylenically unsaturated monomer. The invention further relates to methods for producing and using the present polyalkyl (meth) acrylate. | 2013-03-28 |
20130079266 | Method of Preparing Greases - Provided is a method for preparing a grease composition, which comprises mixing an amine in a lubricating bas oil and an isocyanate in a lubricating base oil under high pressure and high flow rate impingement. In one embodiment, the mixing and reaction occurs in a reaction injection molding device. The resulting grease composition is an extremely low noise grease, being virtually clear of any urea thickener particles. | 2013-03-28 |
20130079267 | Nonflammable compositions comprising fluorinated compounds and use of these compositions - Nonflammable compositions comprising fluorinated compounds selected from the group consisting of hydrofluoroalkanes, hydrofluoroalkenes, partially or perfluorinated aromatic compounds, hydrofluoroethers, and fluoroketones; 1,2-dichloroethylene, especially trans-1,2-dichloroethylene; and a stabilizer. These non-flammable compositions which preferably contain 1,1,1,3,3-pentafluorobutane, can be used especially as solvents for cleaning and defluxing electronic components and for degreasing metals. The compositions further may comprise a propellant, e.g. 1,1,1,2-tetrafluoroethane. These compositions are especially suitable as flushing agent. | 2013-03-28 |
20130079268 | MACHINE DISHWASHER DETERGENT - A liquid cleaning agent containing: a) 20 to 70 wt % water, b) at least one amylase preparation, c) at least one Ca | 2013-03-28 |
20130079269 | METHOD FOR PRODUCING HIGH CONCENTRATION OZONATED WATER AND DEVICE FOR PRODUCING HIGH CONCENTRATION OZONATED WATER - The disclosed device and method produce high concentration ozonated water by connecting a high concentration ozone gas-supplying system that comprises an ozone gas-generating unit ( | 2013-03-28 |
20130079270 | PERFUMING COMPOSITIONS AND USES THEREOF - A perfuming composition capable of prolonging the release of a perfuming component into the surrounding environment when applied on a body surface. The composition includes isocetyl alcohol as a fragrance evaporation modulator in the presence of high amounts of ethanol. Also, consumer articles containing such compositions and methods for the perfuming of a body surface and for increasing the long-lastingness of a perfuming component using these compositions. | 2013-03-28 |
20130079271 | REVERSED BIARYL SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA2C ADRENERGIC RECEPTOR MODULATORS - In its many embodiments, the present invention provides a novel class of biaryl spiroaminooxazoline analogues as modulators of α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the α2C adrenergic receptors using such compounds or pharmaceutical compositions. | 2013-03-28 |
20130079272 | METHODS OF PURIFYING POLYPEPTIDES - The present invention provides methods for purifying a polypeptide from a composition comprising the polypeptide and at least one contaminant and formulations comprising the polypeptide purified by the methods. The methods for purifying include cation exchange material and/or mixed mode material. | 2013-03-28 |
20130079273 | CELL GROWTH-PROMOTING PEPTIDE AND USE THEREOF - The pharmaceutical composition includes at least one pharmaceutically acceptable carrier, and an active ingredient including an artificially synthesized peptide includes: (A) an amino acid sequence constituting a cell-penetrating peptide and (B) an amino acid sequence constituting the signal peptide in amyloid precursor protein (APP) or an N-terminal partial amino acid sequence or C-terminal partial amino acid sequence from the amino acid sequence constituting that signal peptide. | 2013-03-28 |
20130079274 | PHARMACEUTICAL COMPOSITIONS FOR TREATING DYSREGULATED INFLAMMATORY DISEASES - In general, the present invention relates to a new use of lipopeptides or lipoprotein molecules, namely, for treating dysregulated inflammatory diseases. In particular, the present invention relates to pharmaceutical compositions for use in treating dysregulated inflammatory diseases including SIRS, MODS and sepsis. For example, the MALP-2 molecule allows to treat sepsis. | 2013-03-28 |
20130079275 | RECONSTITUTED SURFACTANTS HAVING IMPROVED PROPERTIES - Reconstituted surfactants comprising a lipid carrier, a polypeptide analog of the native surfactant protein SP-C, and a polypeptide analog of the native surfactant protein SP-B are useful for the treatment and/or prophylaxis of RDS and other respiratory disorders. | 2013-03-28 |
20130079276 | LOW PROTEIN INFANT FORMULA WITH INCREASED ESSENTIAL AMINO ACIDS - The present invention concerns an improved balance of the essential branched chain amino acids leucine, isoleucine and valine in infant formula. | 2013-03-28 |
20130079277 | THERAPEUTIC AGENTS COMPRISING ELASTIN-LIKE PEPTIDES - The present invention provides therapeutic agents and compositions comprising elastin-like peptides (ELPs) and therapeutic proteins. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist, insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistance in the body, solubility, and bioavailability. | 2013-03-28 |
20130079278 | Novel Glucagon Analogues - The present invention relates to novel glucagon peptides, to the use of said glucagon peptides in therapy, to methods of treatment comprising administration of said glucagon peptides to patients in need thereof, and to the use of said glucagon peptides in the manufacture of medicaments. The glucagon peptides of the present invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity. | 2013-03-28 |
20130079279 | PHARMACEUTICAL COMPOSITION COMPRISING AVE0010 AND INSULIN GLARGINE - Subject of the present invention is A pharmaceutical composition comprising (a) desPro | 2013-03-28 |
20130079280 | FIBRONECTIN TYPE III DOMAIN-BASED MULTIMERIC SCAFFOLDS - The present invention provides fibronectin type III (Fn3)-based multimeric scaffolds that specifically bind to one or more specific target antigen. The invention further provides bispecific Fn3-derived binding molecules that bind to two or more target antigens simultaneously, fusions, conjugates, and methods to increase the stability of Fn3-based binding molecules. Furthermore, the present invention is related to a prophylactic, therapeutic or diagnostic agent, which contains Fn3-based multimeric scaffolds. | 2013-03-28 |
20130079281 | NEUREGULIN BASED METHODS FOR TREATING HEART FAILURE - The present invention features methods of treating patients with chronic heart failure by administering a neuregulin polypeptide within a dosage range which is both effective and safe. | 2013-03-28 |
20130079282 | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR THE SUSTAINED RELEASE OF SOMATOSTATIN ANALOGS - The invention relates to a process for the preparation of injectable pharmaceutical compositions for the sustained release of somatostatin analogues and to pharmaceutical compositions prepared according to the process. In a preferred aspect the process comprises the steps of combining lanreotide acetate and acetic acid, lyophilizing the resulting mixture only once, and hydrating the lyophilizate. Acetic acid may be added to a desired pH during the final step of the process. | 2013-03-28 |
20130079283 | Erythropoitein Receptor Peptide Formulations and Uses - The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided. | 2013-03-28 |
20130079284 | TREATMENT OF T-CELL MEDIATED DISEASES - The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprising certain diketopiperazines. The invention further provides methods of making improved pharmaceutical compositions of proteins and peptides by either increasing or decreasing the content of diketopiperazines in the compositions and the resultant improved pharmaceutical compositions. | 2013-03-28 |
20130079285 | SOLUBILIZED COLLAGEN FIBERS AND METHOD FOR PRODUCING THE SAME - Provided are novel solubilized collagen fibers with which solubilized collagen can be obtained by instantaneous uniform dissolution in water at the time of use. The solubilized collagen fibers are formed from a solubilized collagen solid content of 66 to 87 wt %, buffer salt content of 2 to 6 wt %, water content of 10 to 22 wt %, and a residual hydrophilic organic solvent content of a trace amount of up to 6 wt % (totaling 100 wt %). The solubilized collagen fibers have an average fineness of 3 to 10 dtx, an isoionic point of 4.5 to 5.0, a water content of 10 to 22 wt %, and residual hydrophilic organic solvent content of a trace amount of up to 6.0 wt %. The solubilized collagen fibers are present uniformly in the direction of fiber length. The buffer salt is selected from sodium citrate, sodium lactate, and sodium phosphate. | 2013-03-28 |
20130079286 | MUTEINS OF HUMAN LIPOCALIN 2 (LCNC,HNGAL) WITH AFFINITY FOR A GIVEN TARGET - The present invention relates to a novel library for the generation of muteins and to novel muteins derived from human lipocalin 2 (Lcn2, hNGAL) and related proteins that bind a given target with detectable affinity. The invention also relates to corresponding nucleic acid molecules encoding such a mutein and to a method for their generation. The invention further relates to a method for producing such a mutein. For example, such muteins may serve to bind and deplete pathological forms of natural biomolecules such as the amyloid beta peptide in Alzheimer's disease or may target the fibronectin extra-domain B, which is associated with tumor neovasculature. | 2013-03-28 |
20130079287 | CAFFEOYLALPHANEOENDORPHIN PEPTIDE DERIVATIVE AND USE THEREOF AS ANTI-ITCHING AND ANTI-ATOPIC AGENTS - Provided is a caffeoylalphaneoendrophin peptide derivative, and use thereof, as an anti-itching agent and an anti-atopic agent. More specifically, provided is a caffeoyl endorphin peptide derivative, which is applicable in a cosmetic material for anti-inflammatory use, such as for an atopic dermatitis treatment, and the like. The caffeoyl endorphin peptide derivative is safe for skin, has resistance to degradation by peptidases, and the like, and also has an excellent stability with respect to temperature change, and the like. | 2013-03-28 |
20130079288 | DIFFERENTIAL EFFECTS OF DRUGS ON TRANSPORT IN A MULTI-LAYER 3D SPHEROID MODEL - Drugs are screened for affects on inhibiting efflux pumps and blocking gap junction communication in tumors by culturing cells to thereby form self-assembled spheroids and incubating the spheroids. Uptake of a substrate of the efflux pump and distribution of a substrate for the efflux pump within the spheroids is imaged to thereby select drugs that inhibit the efflux pump or do not block gap junction communication. Selected drugs can then be employed to treat a tumor. | 2013-03-28 |
20130079289 | Pharmaceutical Compositions - Forms and formulations of VX-950 and uses thereof. | 2013-03-28 |
20130079290 | S1P ANTAGONISTS AS ADJUNCT OCULAR HYPOTENSIVES - The invention provides compositions and methods for further reducing IOP in a subject who has already achieved maximal IOP reduction using known IOP lowering agents. The activity of an ocular hypotensive treatment regimen may be increased by adding an S1P antagonist to prevent S1P mediated reversal as a result of decreased aqueous humor outflow. | 2013-03-28 |
20130079291 | SIALIC ACID (A-(2-6))-D-AMINOPYRANOSE DERIVATIVES, SYNTHESIS METHODS AND USES THEREOF - N-acyl modified sialic acid (α-(2→6))-D-aminopyranose derivatives, their synthesis methods and uses are disclosed. Sialic acid (α-(2→6))-D-aminopyranose derivatives represented by formula 1 are synthesized by using D-aminogalactose (glucose) and sialic acid as raw materials, which are coupled with carrier proteins or polypeptides to obtain glycoprotein (glycopeptide) conjugates. Acetyl is replaced by derivative acyl in the structures of said compounds, therefore the compounds show good activity in antitumor vaccines. | 2013-03-28 |
20130079292 | CYCLIC PEPTIDES BINDING CXCR4 RECEPTOR AND RELATIVE MEDICAL AND DIAGNOSTIC USES - The present invention relates to the identification of new peptides and peptidomimetics which bind the CXCR4 receptor, capable of forming complexes with receptors for chemokines, in particular with CXCR4. The invention also relates to the use of these peptides for the treatment, prevention and diagnosis of diseases which involve chemokine receptors (i.e. neoplasias, metastases, HIV-1 virus infections), and also the mobilization of stem cells of hemopoietic precursors in the case of autologous transplants. Finally, the invention comprises pharmaceutical compositions and diagnostic kits comprising said peptides. | 2013-03-28 |
20130079293 | NEURO-PROTECTIVE EFFECTS OF ADELOSTEMMA GRACILLIMUM AND ITS ISOLATED COMPOUNDS - Isolated compounds from | 2013-03-28 |
20130079294 | EXTRACTS AND ISOLATED FLAVONOIDS FROM EUPHORBIA CUNEATA USEFUL AS ANTI-ULCER AGENTS - The present invention relates to flavonoids isolated from | 2013-03-28 |
20130079295 | TREATMENT OF CARTILAGE RESORPTION - Excessive articular cartilage degradation is treated or prevented by administration to a mammal such as a human | 2013-03-28 |
20130079296 | METHOD FOR ASSAYING LOWER RESPIRATORY TRACT INFECTION OR INFLAMMATION - The present invention relates to a reliable method of prediction of lower respiratory tract infection or inflammation in humans, wherein the level of pancreatic stone protein/regenerating protein (PSP/reg) is determined in serum, and a high level is indicative of the development and the severity of the disease, allowing the classification of patients according to risk. | 2013-03-28 |
20130079297 | KINASE PROTEIN BINDING INHIBITORS - The invention relates to phosphorylation inhibitor compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating cell proliferative disorders, especially cancer. | 2013-03-28 |
20130079298 | NEW LOW MOLECULAR WEIGHT COMPLEXES BETWEEN IRON AND MALTOBIONIC ACID, USE THEREOF FOR INTRAMUSCULAR OR SUBCUTANEOUS ADMINISTRATION IN THE TREATMENT OF ANEMIC STATES, AND NEW PHARMACEUTICAL COMPOSITIONS ADAPTED FOR THESE USES - New low molecular weight complexes between iron and maltobionic acid that can be administered parenterally, preferably intramuscularly or subcutaneously, in the treatment of anemic states, caused by iron deficiencies, and new pharmaceutical compositions adapted for this use. In particular, the invention provides a new complex between preferably trivalent iron and maltobionic acid that is characterized by a molecular weight Mw between 10,000 and 30,000 Da, by a polydispersity of 1.0-1.8 and by an iron content between 25% and 40% by weight. | 2013-03-28 |
20130079299 | Arthritis Therapeutic Agent - Disclosed is a composition for preventing, treating, or alleviating arthritis, and particularly, a composition effective for preventing, treating, or alleviating arthritis comprising β-1,3-1,6-branched D-glucan. The β-1,3-1,6-branched D-glucan of the composition is characterized in that glucoses are linked via a beta-1,3 linkage between two glucose molecules and a gluclose is branched via a linkage between 1 and 6 positions of two glucose molecules in every 1-20 of the beta-1,3 linked glucoses, and the branched glucose is bound with an organic acid. Further, an arthritis therapeutic agent and a health supplement food including the composition, and a method of preventing, treating, or alleviating arthritis including administering a pharmaceutically effective amount of the composition, are disclosed. | 2013-03-28 |
20130079300 | METHOD OF PROVIDING HEMOSTASIS USING FLEXIBLE BIORESORBABLE FOAM - A method of providing hemostasis of bleeding tissue. A flexible bioresorbable foam is formed that consists essentially of carboxymethylcellulose. The flexible bioresorbable foam is crosslinked. Chain scission is performed on the crosslinked flexible bioresorbable foam to provide the flexible bioresorbable foam with a selected in-vivo residence time of between about 3 days and about 14 days. Hemostasis is caused by applying the flexible bioresorbable foam to bleeding tissue. The flexible bioresorbable foam is resorbed in-vivo. The selected in-vivo residence time is a time between the flexible bioresorbable foam being applied to the tissue and the flexible bioresorbable foam having been substantially completely absorbed into the tissue. | 2013-03-28 |
20130079301 | Hypertonic dextran solution and methods of treating and preventing recurrent corneal erosion - An ophthalmic solution is provided. The ophthalmic solution is hypertonic. The ophthalmic solution includes a polysaccharide having an average molecular weight of between about 40,000 grams per mole and about 150,000 grams per mole. A packaged ophthalmic solution for preventing the ophthalmic solution from being exposed to CO | 2013-03-28 |
20130079302 | N-[(HET)ARYLALKYL)] PYRAZOLE(THIO)CARBOXAMIDES AND THEIR HETEROSUBSTITUTED ANALOGUES - The present invention relates to fungicidal N-[(het)arylalkyl)]pyrazolecarboxamide or thiocarboxamide and their heterosubstituted analogues, their process of preparation and intermediate compounds for their preparation, their use as fungicides, particularly in the form of fungicidal compositions and methods for the control of phytopathogenic fungi of plants using these compounds or their compositions. | 2013-03-28 |
20130079303 | Inhibitors of PI3 Kinase and/or mTOR - The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof; | 2013-03-28 |
20130079304 | Pharmaceutical Compositions for the Treatment of Fungal Infections - Synergistic combinations of a squalene epoxidase inhibitor and a leucyl-tRNA synthetase inhibitor are provided, which are useful in particular in the treatment of diseases involving fungal or suspected fungal infection, for immunomodulation or immunosuppression in conditions in which fungal or suspected fungal colonisation of e.g. the skin or nail plays a role, such as atopic dermatitis, acne vulgaris, seborrhoeic dermatitis, rosacea or onychomycosis, and in situations of fungal resistance. | 2013-03-28 |
20130079305 | 3-SUBSTITUTED VINYLBORONATES AND USES THEREOF - 3-substituted vinylboronates and their use in the treatment of cancer such as colorectal cancer are disclosed. In some embodiments, the 3-substituted vinylboronates have the general Formula I: | 2013-03-28 |
20130079306 | HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR - A novel heterocyclic compound or a salt thereof useful for selectively inhibiting the degradation of p27 | 2013-03-28 |
20130079307 | MEDICINE, FOOD AND DRINK OR FEED CONTAINING SPHINGOMYELIN - It is intended to find novel pharmaceutical use of sphingomyelin and to provide preventive or therapeutic agents for various diseases as well as a food and drink product and feed comprising any of these agents. The present invention provides a pharmaceutical agent which contains sphingomyelin as an active ingredient and is any of the following agents: 1) a sialomucin secretion promoter, 2) an agent for preventing drunken sickness (hangover), 3) an antiallergic agent, 4) an antioxidant, 5) an agent for defending against infection, 6) a hair growth agent, 7) a therapeutic agent for demyelinating disease, 8) an anti-pigmentation agent, 9) an anti-inflammatory agent, and 10) an agent for improving learning ability. The present invention also provides a food and drink product or feed, characterized by comprising the agent. It is preferred that the sphingomyelin should be derived from milk. | 2013-03-28 |
20130079308 | Beta-Hydroxy-Gamma-Aminophosphonates and Methods for the Preparation and Use Thereof - The present invention provides β-hydroxy-γ-aminophosphonates, β-amino-γ-aminophosphonates, and analogs thereof that inhibit carnitine acyltransferases. The invention also provides compositions comprising these β-hydroxy-γ-aminophosphonates, β-amino-γ-aminophosphonates, and analogs, and methods of the use of such compounds and compositions in the treatment, amelioration or prevention of pathological conditions, diseases or disorders that are linked with fatty acid metabolism, such as non-insulin dependent diabetes or obesity. The invention also provides processes for the preparation of such compounds and compositions. | 2013-03-28 |
20130079309 | Method Of Treating Acute Lung Injury Using Sphingosine 1 Phosphate Analogs Or Sphingosine 1 Phosphate Receptor Agonists - The invention provides methods for treating or reducing the risk of developing acute lung injury manifested by increased vascular permeability. Also provided are pharmaceutical compositions comprising an FTY720 analog or derivative and/or SEW 2871 for use in the disclosed methods. The invention also provides methods for treating or reducing the risk of developing acute lung injury resulting from dysregulation of ceramide/sphingolipid pathway, more specifically, acute lung injury resulting from radiation. | 2013-03-28 |
20130079310 | STATIN AND OMEGA 3 FATTY ACIDS FOR REDUCTION OF APOLIPOPROTEIN-B LEVELS - A composition and a method of treatment utilizing a combination of statins (or HMG-CoA reductase inhibitors), a class of drug used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA represent about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition are taught. | 2013-03-28 |
20130079311 | COMPOSITIONS AND KITS FOR COMPOUNDING PHARMACEUTICALS - The invention provides compositions and methods for the convenient compounding of pharmaceuticals. Single and multiple unit of use kits are provided which contain all the necessary components required for preparing a compounded pharmaceutical. The kits of the invention include a first container having a first active agent and a second container having at least one second inactive agent. The kits of the invention are also useful for compounding veterinary pharmaceuticals. | 2013-03-28 |
20130079312 | Method of Treating Hair Loss Due to Systemic Chemotherapy - Methods and composition for preventing and/or treating hair loss associated with the administration of cancer chemotherapy using vasoconstrictors are disclosed. Optionally corticosteroids are also in the formulation. | 2013-03-28 |
20130079313 | DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS - The invention relates to inhibitors of the phosphodiesterase 4 (PDE4) enzyme. More particularly, the invention relates to compounds that are derivatives of 1-phenyl-2-pyridinyl alkyl alcohols, methods of preparing such compounds, compositions containing them and therapeutic use thereof. | 2013-03-28 |
20130079314 | ALOE VERA EXTRACT, METHOD OF PRODUCING ALOE VERA EXTRACT, AND HYPERGLYCEMIA IMPROVING AGENT - The present invention provides: an | 2013-03-28 |
20130079315 | Ophthalmic Gel Compositions - A suspension comprising an ophthalmic active that has a solubility in water at 25° C. and a pH of 7 of less than 0.1 times the concentration of the active in mg/mL in the suspension, the ophthalmic active suspended in a formulation vehicle. The formulation vehicle comprises a lightly cross-linked carboxy-containing polymer and a concentration of ionic salt components to provide the suspension with a calculated ionic strength of less than 0.1. The suspension has the following rheological properties, G′>G″ and a suspension yield value of greater than 1 Pa. Also, upon addition of 30 mL of the suspension to a volume of 6 mL to 12 mL of simulated tear fluid, the resulting tear mixture transitions to a liquid form wherein, G″>G′ and the tear mixture has a yield value of less than 0.1 Pa. | 2013-03-28 |
20130079316 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE - The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-κB for the treatment or prevention of muscular wasting disease, including muscular dystrophy. | 2013-03-28 |
20130079317 | METHODS FOR TREATMENT OF DISEASES - The present disclosure relates to methods of treating a range of diseases or conditions. The methods involve administration of a superoxide dismutase mimetic. | 2013-03-28 |
20130079318 | BETA-LACTAMASE INHIBITORY COMPOUNDS - Inhibitors of the enzyme beta-lactamase are provided. The compounds are adapted to inhibit beta-lactamase as produced by beta-lactam resistant bacterial strains. Methods of treatment of beta-lactam resistant bacterial infections in patients are provided. | 2013-03-28 |
20130079319 | CEPHEM COMPOUND HAVING PSEUDO-CATECHOL GROUP - A compound of the formula: | 2013-03-28 |
20130079320 | Amine Substituted Methanesulfonamide Derivatives as Vanilloid Receptor Ligands - The invention relates to amine substituted methanesulfonamide derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders. | 2013-03-28 |
20130079321 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE - Pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 2013-03-28 |
20130079322 | CRYSTALLINE OF CARBAPENEM DERIVATIVE OR ITS HYDRATE, PREPARATION METHODS AND USES THEREOF - The present invention relates to a crystalline form of carbapenems derivative (4R,5S,6S)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-3-(((3S,5S)-5-((4-sulfamoylbenzyl)carbamoyl)pyrrolidin-3-yl)thio)-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid_as represented by formula (I) or hydrate thereof and the preparation methods thereof, wherein said method comprise: dissolving the compound as represented by formula (I) by an aqueous solution of N,N′-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), and then adding a poor solvent dropwise to this solution, filtering and drying to obtain a crystal. Another method comprises: formulating the compound as represented by formula (I) as an aqueous suspension; after adjusting pH until complete dissolution, adding a mixed solvent of organic solvent/water with a certain volume ratio; adjusting pH to 5.4-7.0, cooling to low temperature, filtering and drying to obtain a crystal. The invention also relates to the use of the crystalline form of compound A or hydrate thereof in the preparation of a medicament for treating and/or preventing infectious diseases. The invention further relates to a pharmaceutical composition comprising the crystalline form of compound A or hydrate thereof and one or more pharmaceutical carriers and/or diluents. | 2013-03-28 |
20130079323 | GYRASE INHIBITORS - Novel gyrase inhibitors and related compositions and methods are useful for impeding bacterial growth. Compounds of Formula (I), are disclosed: Formula (I), wherein Y is N or CH; Z is N or CR | 2013-03-28 |
20130079324 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES - The present invention relates to compounds of formula (I) | 2013-03-28 |
20130079325 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS - Pyridine and pyrimidine compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like. | 2013-03-28 |
20130079326 | N-PHENYL IMIDAZOLE CARBOXAMIDE INHIBITORS OF 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 - The present invention provide Imidazole Carboxamide Compounds of Formula (I): wherein D, T, R | 2013-03-28 |
20130079327 | PURINONE DERIVATIVE - Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate. | 2013-03-28 |
20130079328 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY - The present invention relates to compositions and methods for modulating the Wnt signaling pathway, using compounds having Formula (1) and (3): wherein A, B, Y and Z all represent rings, and R | 2013-03-28 |
20130079329 | INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/Beta-CATENIN SIGNALING PATHWAY INHIBITORS - Indazole-3-carboxamide compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole-3-carboxamide compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states. | 2013-03-28 |
20130079330 | Fused Thiazole Derivatives as Kinase Inhibitors - A series of 6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-4(5H)-one derivatives, which are substituted in the 2-position by a substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. | 2013-03-28 |
20130079331 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE - Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z | 2013-03-28 |
20130079332 | TOPICAL PHARMACEUTICAL COMPOSITION COMPRISING A CHOLINERGIC AGENT OR A CALCIUM CHANNEL BLOCKER - A method and composition are provided for the treatment of an anorectal disorder and for controlling the pain associated therewith. The method comprises administering to a subject in need of such treatment therapeutically effective amounts of a calcium channel blocker either alone or together with a nitric oxide donor. Amlodipine, anipamil, barnidipine, benidipine, bepridil, darodipine, diltiazem, efonidipine, felodipine, isradipine, lacidipine, lercanidipine, lidoflazine, manidipine, mepirodipine, nicardipine, nifedipine, niludipine, nilvadipine, nimodipine, nisoldipine, nitrendipine, perhexiline, tiapamil, verapamil and pharmaceutically acceptable salts thereof, are suitable calcium channel blockers. | 2013-03-28 |
20130079333 | OXY-CYCLOHEXYL-4H,6H-5-OXA-2,3,10B-TRIAZA-BENZO[E]AZULENES AS V1A ANTAGONISTS - The present invention provides 4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulenes of the formula | 2013-03-28 |
20130079334 | Compositions for Delivery of Insoluble Agents - Compositions and methods of making the same for in vivo delivery of lixivaptan to a subject in need thereof are described. The composition includes a substantially water-insoluble pharmacologically active agent (e.g., lixivaptan) and a substantially water-insoluble matrix forming material (e.g., a Vitamin E semi-ester), wherein the pharmacologically active agent is dispersed in said matrix forming material, and wherein the composition delivers said substantially water-insoluble pharmacologically active agent upon exposure to physiological medium. | 2013-03-28 |
20130079335 | Benzotriazolodiazepine Compounds Inhibitors Of Bromodomains - Benzodiazepine compounds, pharmaceutical compositions containing such compounds and to their use in therapy. | 2013-03-28 |
20130079336 | Treatment of Prolonged Status Epilepticus - Methods for terminating, preventing, and/or treating status epilepticus are generally provided. The method can include administering a prophylactically or therapeutically effective amount of stiripentol or a related compound thereof to an individual in need of treatment of status epilepticus. The individual can be in need of treatment of prolonged status epilepticus, refractory status epilepticus, and/or benzodiazepine-resistant status epilepticus. | 2013-03-28 |
20130079337 | PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF - The invention relates to compounds corresponding to formula (I) | 2013-03-28 |
20130079338 | Selective NR2B Antagonists - The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system. | 2013-03-28 |
20130079339 | TRPV1 VANILLOID RECEPTOR ANTAGONISTS WITH A BICYCLIC PORTION - The invention discloses compounds of formula I | 2013-03-28 |
20130079340 | Benzothiazoles Having Histamine H3 Receptor Activity - Certain novel benzothiazoles and benzoxazoles, e.g., 2-(piperazin-1-yl)benzothiazoles and 2-(piperazin-1-yl)benzoxazoles, optionally substituted in the 3 and/or 4 positions of the piperazine rings, having histamine H3 antagonistic activity can be used in pharmaceutical compositions. | 2013-03-28 |
20130079341 | THIENO (2, 3B) PYRAZINE COMPOUNDS AS B-RAF INHIBITORS - The invention relates to compounds according to general Formula (I) or a pharmaceutically acceptable salt thereof. The compounds can be used for the treatment of cancer. | 2013-03-28 |
20130079342 | HETEROCYCLIC COMPOUNDS AND THEIR USES - Substituted bicyclic heteroaryls of the following formulae and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer. | 2013-03-28 |